HER2 Support Group Forums - View Single Post - Need thoughts from anyone who had a recurrence to skin

Lani · 11-30-2012, 04:51 PM

looks like you already commented on it. Did you try it?

07-07-2012, 04:23 PM #1
Lani
Senior Member

Join Date: Mar 2006
Posts: 4,109
already approved topical treatment effective vs skin mets
article did not mention her2 status of any of the involved patients, however

Clin Cancer Res. 2012 Jul 5. [Epub ahead of print]
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer JL, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S.
Source
Medicine, NYU School of Medicine.
Abstract
PURPOSE:
Skin metastases of breast cancer remain a therapeutic challenge. Toll-like receptor 7 agonist imiquimod is an immune response modifier and can induce immune-mediated rejection of primary skin malignancies when topically applied. Here we tested the hypothesis that topical imiquimod stimulates local anti-tumor immunity and induces the regression of breast cancer skin metastases.
EXPERIMENTAL DESIGN:
A prospective clinical trial was designed to evaluate the local tumor response rate of breast cancer skin metastases treated with topical imiquimod, applied 5 days/week for 8 weeks. Safety and immunological correlates were secondary objectives.
RESULTS:
Ten patients were enrolled and completed the study. Imiquimod treatment was well tolerated, with only grade 1-2 transient local and systemic side effects consistent with imiquimod's immunomodulatory effects. Two patients achieved a partial response (20%; 95% CI 3% - 56%). Responders showed histological tumor regression with evidence of an immune-mediated response, demonstrated by changes in the tumor lymphocytic infiltrate and locally produced cytokines.
CONCLUSIONS:
Topical imiquimod is a beneficial treatment modality for breast cancer metastatic to skin/chest wall and is well tolerated. Importantly, imiquimod can promote a pro-immunogenic tumor microenvironment in breast cancer. Preclinical data generated by our group suggest even superior results with a combination of imiquimod and ionizing radiation and we are currently testing in patients whether the combination can further improve anti-tumor immune and clinical responses.
PMID: 22767669 [

07-08-2012, 10:28 PM #2
karen z
Senior Member

Join Date: Apr 2008
Posts: 1,027
Re: already approved topical treatment effective vs skin mets
thanks for the post.

07-09-2012, 09:31 AM #3
yanyan
Senior Member

Join Date: Apr 2011
Posts: 215
Re: already approved topical treatment effective vs skin mets
Thanks for posting. I will share this with my onco. I wonder if this will be a better option than to have a skin graft for localized skin mets.

11-30-2012, 04:51 PM	#11
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Re: Need thoughts from anyone who had a recurrence to skin looks like you already commented on it. Did you try it? 07-07-2012, 04:23 PM #1 Lani Senior Member Join Date: Mar 2006 Posts: 4,109 already approved topical treatment effective vs skin mets article did not mention her2 status of any of the involved patients, however Clin Cancer Res. 2012 Jul 5. [Epub ahead of print] Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer JL, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S. Source Medicine, NYU School of Medicine. Abstract PURPOSE: Skin metastases of breast cancer remain a therapeutic challenge. Toll-like receptor 7 agonist imiquimod is an immune response modifier and can induce immune-mediated rejection of primary skin malignancies when topically applied. Here we tested the hypothesis that topical imiquimod stimulates local anti-tumor immunity and induces the regression of breast cancer skin metastases. EXPERIMENTAL DESIGN: A prospective clinical trial was designed to evaluate the local tumor response rate of breast cancer skin metastases treated with topical imiquimod, applied 5 days/week for 8 weeks. Safety and immunological correlates were secondary objectives. RESULTS: Ten patients were enrolled and completed the study. Imiquimod treatment was well tolerated, with only grade 1-2 transient local and systemic side effects consistent with imiquimod's immunomodulatory effects. Two patients achieved a partial response (20%; 95% CI 3% - 56%). Responders showed histological tumor regression with evidence of an immune-mediated response, demonstrated by changes in the tumor lymphocytic infiltrate and locally produced cytokines. CONCLUSIONS: Topical imiquimod is a beneficial treatment modality for breast cancer metastatic to skin/chest wall and is well tolerated. Importantly, imiquimod can promote a pro-immunogenic tumor microenvironment in breast cancer. Preclinical data generated by our group suggest even superior results with a combination of imiquimod and ionizing radiation and we are currently testing in patients whether the combination can further improve anti-tumor immune and clinical responses. PMID: 22767669 [ 07-08-2012, 10:28 PM #2 karen z Senior Member Join Date: Apr 2008 Posts: 1,027 Re: already approved topical treatment effective vs skin mets thanks for the post. 07-09-2012, 09:31 AM #3 yanyan Senior Member Join Date: Apr 2011 Posts: 215 Re: already approved topical treatment effective vs skin mets Thanks for posting. I will share this with my onco. I wonder if this will be a better option than to have a skin graft for localized skin mets.